
Dörte Huscher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1950064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases, 2009, 68, 1119-1124.	0.9	392
2	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases, 2015, 74, 1188-1194.	0.9	340
3	Brief Report: Pulmonary Function Tests: High Rate of Falseâ€Negative Results in the Early Detection and Screening of Sclerodermaâ€Related Interstitial Lung Disease. Arthritis and Rheumatology, 2015, 67, 3256-3261.	5.6	157
4	IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1639-1645.	0.9	115
5	Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Research and Therapy, 2009, 11, R22.	3.5	108
6	Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary SjA¶gren's Syndrome: A Pilot Study. Arthritis Care and Research, 2013, 65, 1862-1868.	3.4	104
7	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	5.6	100
8	Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres. Annals of the Rheumatic Diseases, 2010, 69, 1803-1808.	0.9	94
9	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 58, 2845-2853.	6.7	91
10	Evolution of cost structures in rheumatoid arthritis over the past decade. Annals of the Rheumatic Diseases, 2015, 74, 738-745.	0.9	90
11	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
12	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	1.9	60
13	Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 2011, 49, 733-742.	2.9	56
14	Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1194-1199.	0.9	55
15	Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. European Heart Journal, 2019, 40, 2021-2028.	2.2	54
16	Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum–induced arthritis in vivo. Arthritis and Rheumatism, 2009, 60, 1998-2007.	6.7	49
17	Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Research and Therapy, 2009, 11, R28.	3.5	45
18	A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients. International Journal of Molecular Sciences, 2017, 18, 583.	4.1	45

DöRTE HUSCHER

#	Article	IF	CITATIONS
19	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatology International, 2018, 38, 569-577.	3.0	43
20	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmunity Reviews, 2020, 19, 102452.	5.8	43
21	Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters. Cellular and Molecular Immunology, 2015, 12, 483-492.	10.5	42
22	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Annals of the Rheumatic Diseases, 2014, 73, 191-197.	0.9	41
23	Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Research and Therapy, 2016, 18, 149.	3.5	36
24	Mobile App-based documentation of patient-reported outcomes—Â3-months results from a proof-of-concept study on modern rheumatology patient management. Arthritis Research and Therapy, 2021, 23, 121.	3.5	34
25	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.9	31
26	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). Current Respiratory Medicine Reviews, 2015, 11, 175-183.	0.2	30
27	Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Longâ€ŧerm data of the SIGNS study. European Journal of Haematology, 2017, 99, 169-177.	2.2	29
28	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clinical Research in Cardiology, 2018, 107, 460-470.	3.3	29
29	Ventilation Time of the Middle Ear in Otitis Media With Effusion (OME) After CO2 Laser Myringotomy. Laryngoscope, 2002, 112, 661-668.	2.0	28
30	Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clinical and Experimental Rheumatology, 2013, 31, 256-62.	0.8	27
31	Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open, 2015, 1, e000033-e000033.	3.8	24
32	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 2011, 70, 1197-1202.	0.9	21
33	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Journal of Clinical Medicine, 2020, 9, 1456.	2.4	21
34	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	1.9	20
35	Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study. BMC Geriatrics, 2020, 20, 22.	2.7	19
36	Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. Bone, 2013, 55, 93-101.	2.9	18

DöRTE HUSCHER

#	Article	IF	CITATIONS
37	Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database. Rheumatology International, 2020, 40, 1639-1647.	3.0	18
38	Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatology International, 2012, 32, 1469-1473.	3.0	17
39	Gender differences in frailty transition and its prediction in community-dwelling old adults. Scientific Reports, 2022, 12, 7341.	3.3	17
40	Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study. Clinical and Experimental Rheumatology, 2015, 33, 34-43.	0.8	16
41	Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 2176-2183.	0.9	15
42	Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Science and Medicine, 2014, 1, e000059.	2.7	15
43	Nationwide Registryâ€Based Analysis of Infective Endocarditis Risk After Pulmonary Valve Replacement. Journal of the American Heart Association, 2022, 11, e022231.	3.7	15
44	Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Therapeutic Advances in Neurological Disorders, 2016, 9, 165-179.	3.5	14
45	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.9	12
46	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 2019, 34, 253-261.	0.9	12
47	Age and the Course of GFR in Persons Aged 70 and Above. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1119-1128.	4.5	11
48	Elevated Psychosocial Stress at Work in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 227-234.	2.0	10
49	Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling. BMC Musculoskeletal Disorders, 2014, 15, 31.	1.9	9
50	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.6	9
51	Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry. Journal of Clinical Immunology, 2013, 33, 67-71.	3.8	8
52	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. Cardiovascular Diagnosis and Therapy, 2021, 11, 1255-1268.	1.7	8
53	Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations. Current Rheumatology Reviews, 2010, 6, 145-150.	0.8	4
54	Performance of risk prediction scores for cardiovascular mortality in older persons: External validation of the SCORE OP and appraisal. PLoS ONE, 2020, 15, e0231097.	2.5	4

DöRTE HUSCHER

#	Article	IF	CITATIONS
55	Development of a prediction model for mortality and cardiovascular outcomes in older adults taking into account AZGP1. Scientific Reports, 2021, 11, 11792.	3.3	4
56	Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. Zeitschrift Fur Gesundheitswissenschaften, 2012, 20, 289-296.	1.6	3
57	Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study. Age and Ageing, 2021, 50, 1173-1181.	1.6	3
58	SP212INCIDENCE OF ACUTE KIDNEY INJURY IN A COMMUNITY-BASED POPULATION OF OLDER ADULTS - DATA FROM THE BERLIN INITIATIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
59	FP415NO ASSOCIATION OF AZGP1 SERUM LEVELS WITH MORTALITY AND CARDIOVASCULAR EVENTS IN A COMMUNITY-BASED POPULATION OF OLDER ADULTS - DATA FROM THE BERLIN INITIATIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
60	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 2020, 35, 460-461.	0.9	0